



(51) International Patent Classification:

C12N 15/864 (2006.01) A61P 9/00 (2006.01)
C40B 40/10 (2006.01) A61P 21/00 (2006.01)
A61K 35/76 (2015.01)

(21) International Application Number:

PCT/SG2024/050344

(22) International Filing Date:

23 May 2024 (23.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202302405W 25 August 2023 (25.08.2023) SG

(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way,

#20-10 Connexis North Tower, Singapore 138632 (SG).


(72) Inventors: **KENG, Choong Tat**; 60 Biopolis Street, Genome, Singapore 138672 (SG). **CHEW, Wei Leong**; 60 Biopolis Street, Genome, Singapore 138672 (SG). **HAJIS, Muhammad Irfan Bin**; 60 Biopolis Street, Genome, Singapore 138672 (SG). **SHEN, Yanyin Kimberle**; 60 Biopolis Street, Genome, Singapore 138672 (SG).

(74) Agent: **CHUNG, Jing Yeng**; Marks & Clerk Singapore LLP, Tanjong Pagar Post Office, P.O. Box 636, Singapore 910816 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMPOSITION AND METHODS FOR IDENTIFICATION OF NOVEL AAV VARIANTS FOR DIFFERENTIATED GENE DELIVERY TO CARDIOMYOCYTES AND/OR SKELETAL MYOFIBERS

FIG. 1



(57) Abstract: The present invention relates to the provision of recombinant adeno-associated virus (rAAV) -based delivery vectors comprising short peptide inserts of at least 5 amino acid length, which show enhanced transduction efficiency in one or more muscle cells, particularly in cardiomyocytes and/or skeletal muscle cells. The rAAV vectors of the present disclosure are suitable for use in the treatment and/or prophylaxis of a cardiac-related and/or muscle-related disease or disorder and/or for use in gene therapy. Also provided are methods of treating cardiac-related and/or muscle-related diseases or disorders.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*